NO20062063L - Forbindelser og fremgangsmater for behandling og forbyggelse av treningsinduserte hjerte arrytmier - Google Patents
Forbindelser og fremgangsmater for behandling og forbyggelse av treningsinduserte hjerte arrytmierInfo
- Publication number
- NO20062063L NO20062063L NO20062063A NO20062063A NO20062063L NO 20062063 L NO20062063 L NO 20062063L NO 20062063 A NO20062063 A NO 20062063A NO 20062063 A NO20062063 A NO 20062063A NO 20062063 L NO20062063 L NO 20062063L
- Authority
- NO
- Norway
- Prior art keywords
- methods
- exercise
- prevention
- compounds
- treatment
- Prior art date
Links
- 206010003119 arrhythmia Diseases 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title 1
- 206010049418 Sudden Cardiac Death Diseases 0.000 abstract 3
- KCWGETCFOVJEPI-UHFFFAOYSA-N jtv-519 Chemical compound C1C2=CC(OC)=CC=C2SCCN1C(=O)CCN(CC1)CCC1CC1=CC=CC=C1 KCWGETCFOVJEPI-UHFFFAOYSA-N 0.000 abstract 3
- KYVHGCKMVJDCNV-UHFFFAOYSA-N 1,4-benzothiazepine Chemical compound S1C=CN=CC2=CC=CC=C12 KYVHGCKMVJDCNV-UHFFFAOYSA-N 0.000 abstract 1
- 102100027914 Peptidyl-prolyl cis-trans isomerase FKBP1B Human genes 0.000 abstract 1
- 102000019027 Ryanodine Receptor Calcium Release Channel Human genes 0.000 abstract 1
- 108010012219 Ryanodine Receptor Calcium Release Channel Proteins 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 230000002194 synthesizing effect Effects 0.000 abstract 1
- 108010029517 tacrolimus binding protein 1B Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5076—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving cell organelles, e.g. Golgi complex, endoplasmic reticulum
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/326—Arrhythmias, e.g. ventricular fibrillation, tachycardia, atrioventricular block, torsade de pointes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Heart & Thoracic Surgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/680,988 US20040229781A1 (en) | 2000-05-10 | 2003-10-07 | Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias |
| PCT/US2004/032550 WO2005037195A2 (fr) | 2003-10-07 | 2004-10-04 | Composes et methodes de traitement et de prevention d'arythmies cardiaques induites par l'exercice physique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20062063L true NO20062063L (no) | 2006-07-07 |
Family
ID=34465444
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20062063A NO20062063L (no) | 2003-10-07 | 2006-05-08 | Forbindelser og fremgangsmater for behandling og forbyggelse av treningsinduserte hjerte arrytmier |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20040229781A1 (fr) |
| EP (1) | EP1684735A4 (fr) |
| JP (1) | JP2007507536A (fr) |
| KR (1) | KR20060110290A (fr) |
| CN (1) | CN100502845C (fr) |
| AU (1) | AU2004281672A1 (fr) |
| BR (1) | BRPI0415434A (fr) |
| CA (1) | CA2541847A1 (fr) |
| EA (1) | EA011357B1 (fr) |
| MA (1) | MA28146A1 (fr) |
| NO (1) | NO20062063L (fr) |
| SG (1) | SG147414A1 (fr) |
| WO (1) | WO2005037195A2 (fr) |
| ZA (1) | ZA200603593B (fr) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7393652B2 (en) | 2000-05-10 | 2008-07-01 | The Trustees Of Columbia University In The City Of New York | Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2) |
| US7718644B2 (en) * | 2004-01-22 | 2010-05-18 | The Trustees Of Columbia University In The City Of New York | Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof |
| US7879840B2 (en) | 2005-08-25 | 2011-02-01 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
| US8022058B2 (en) | 2000-05-10 | 2011-09-20 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
| US7544678B2 (en) | 2002-11-05 | 2009-06-09 | The Trustees Of Columbia University In The City Of New York | Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) |
| AU2004220548A1 (en) | 2003-03-07 | 2004-09-23 | The Trustees Of Columbia University, In The City Of New York | Type 1 ryanodine receptor-based methods |
| US8710045B2 (en) | 2004-01-22 | 2014-04-29 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the ryanodine receptors |
| US20070264319A1 (en) * | 2004-09-01 | 2007-11-15 | Lebo David B | Transdermal Antiemesis Delivery System, Method and Composition Therefor |
| US7704990B2 (en) * | 2005-08-25 | 2010-04-27 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
| WO2008140592A2 (fr) * | 2006-11-29 | 2008-11-20 | Armgo Pharma, Inc. | 1,4-benzothiazépines radioactivement marquées et procédés de criblage de composés qui lient les récepteurs de la ryanodine |
| ME01989B (fr) * | 2008-03-03 | 2012-08-31 | Servier Lab | Procédé pour préparer des benzothiazépines à partir de gamma-aminoalkylbenzènes |
| EP2418950A4 (fr) * | 2009-04-15 | 2012-10-24 | State Of Oregon By & Through The State Board Of Higher Education On Behalf Of Portland State Unv | Composés et procédés de modulation de l'activité des canaux de libération de calcium |
| EP2708535A1 (fr) * | 2012-05-11 | 2014-03-19 | Les Laboratoires Servier | Agents pour le traitement de troubles impliquant la modulation de récepteurs de la ryanodine |
| ES2643856B1 (es) | 2016-05-24 | 2018-08-03 | Universidad Del Pais Vasco / Euskal Herriko Unibertsitatea | Triazoles para la regulación de la homeostasis de calcio intracelular |
| IL312745A (en) * | 2021-11-16 | 2024-07-01 | Armgo Pharma Inc | Therapeutic compounds |
Family Cites Families (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1060786A (en) * | 1963-10-09 | 1967-03-08 | Wander Ag Dr A | Process for the preparation of lactams |
| DE3561317D1 (en) * | 1984-01-27 | 1988-02-11 | Ajinomoto Kk | Manufacture of heptanoic acid derivatives |
| US4841055A (en) * | 1985-03-25 | 1989-06-20 | Japan Tobacco Inc. | Desmosine derivatives and reagent for preparing artificial antigens |
| US4723012A (en) * | 1985-03-25 | 1988-02-02 | Japan Tobacco Inc. | Desmosine derivatives having a disulfide bond and preparation of artificial antigen using the same |
| US6956032B1 (en) * | 1986-04-18 | 2005-10-18 | Carnegie Mellon University | Cyanine dyes as labeling reagents for detection of biological and other materials by luminescence methods |
| US5124056A (en) * | 1987-07-24 | 1992-06-23 | Exxon Chemical Patents Inc. | Polymer substituted amido-amine Mannich Base lubricant dispersant additives |
| JPS6445706A (en) * | 1987-08-17 | 1989-02-20 | Sumitomo Electric Industries | Production of composite carbon nitride |
| US5210266A (en) * | 1987-12-03 | 1993-05-11 | Dainippon Pharmaceutical Co., Ltd. | N-substituted mercaptopropanamide derivatives |
| EP0368063B1 (fr) * | 1988-11-05 | 1992-06-10 | Bayer Ag | Procédé pour la chlorination dans le noyau d'hydrocarbures aromatiques |
| US5223508A (en) * | 1988-12-27 | 1993-06-29 | Kirin Beer Kabushiki Kaisha | Pyridyl carboximidamide compounds useful in treating blood pressure |
| ES2084706T3 (es) * | 1989-09-30 | 1996-05-16 | Kirin Brewery | Metodo de produccion de plantones. |
| KR940000166B1 (ko) * | 1989-11-09 | 1994-01-08 | 니혼다바고 상교오 가부시기가이샤 | 신규 글루코사민 유도체 및 이것을 막 구성성분으로서 함유한 리포솜 |
| US5204462A (en) * | 1990-03-30 | 1993-04-20 | Japan Tobacco, Inc. | 4h-3,1-benzoxazin-4-one derivative |
| US5517652A (en) * | 1990-05-30 | 1996-05-14 | Hitachi, Ltd. | Multi-media server for treating multi-media information and communication system empolying the multi-media server |
| JP2651043B2 (ja) * | 1990-07-10 | 1997-09-10 | 麒麟麦酒株式会社 | ジフェニルメチルピペラジン誘導体 |
| JP2703408B2 (ja) * | 1990-12-28 | 1998-01-26 | 麒麟麦酒株式会社 | １，４‐ベンゾチアゼピン誘導体 |
| DE4102103A1 (de) * | 1991-01-25 | 1992-08-20 | Bayer Ag | Substituierte benzoxazepine und benzthiazepine, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln |
| US5182272A (en) * | 1991-05-03 | 1993-01-26 | G. D. Searle & Co. | 8-substituted-dibenz[b,f][1,4]oxazepine-10(11)-carboxylic acid, substituted hydrazides, pharmaceutical compositions, and methods for treating pain |
| US5180720A (en) * | 1991-05-03 | 1993-01-19 | G. D. Searle & Co. | 2- and 3-alkoxy or hydroxy-8-substituted-dibenz[b,f]-[1,4]oxazepine-10(11H)-carboxylic acid, substituted hydrazides and methods for treating pain |
| WO1993007129A1 (fr) * | 1991-10-11 | 1993-04-15 | Yoshitomi Pharmaceutical Industries, Ltd. | Medicament utilise pour traiter l'osteoporose et compose de diazepine |
| WO1993013082A1 (fr) * | 1991-12-20 | 1993-07-08 | G.D. Searle & Co. | Dibenzoxazepines ou dibenzothiazepines substituees et utilisation desdites substances en tant qu'antagonistes des prostaglandines e¿2? |
| MX9300433A (es) * | 1992-01-28 | 1994-07-29 | Kirin Brewery | Compuestos de piridincarboximidamina y composiciones farmaceuticas que los contienen. |
| GB9203347D0 (en) * | 1992-02-17 | 1992-04-01 | Wellcome Found | Hypolipidaemic compounds |
| US5387684A (en) * | 1992-03-25 | 1995-02-07 | The Green Cross Corporation | Isoindazole compound |
| US5304644A (en) * | 1992-04-15 | 1994-04-19 | G. D. Searle & Co. | 1-,2-,3-,4-,5-,6-,7-,8- and/or 9 substituted dibenzoxazepine compounds, pharmaceutical compositions and methods for treating pain |
| CA2139362A1 (fr) * | 1992-07-02 | 1994-01-20 | Kooji Kagara | Intermediaire original pour la synthese et la production d'un derive d'acides amines |
| EP0656356A1 (fr) * | 1992-08-21 | 1995-06-07 | Japan Tobacco Inc. | Compose dioxacycloalcane a activite inhibitrice de la renine |
| HUT71819A (en) * | 1992-11-09 | 1996-02-28 | Boots Co Plc | 1,4-benzothiazepine derivatives and pharmaceutical compositions containing them |
| IL108633A (en) * | 1993-02-15 | 1998-07-15 | Wellcome Found | History of Benzothiazepine Hypolipidemic Preparation and Pharmaceutical Preparations Containing Them |
| US5719155A (en) * | 1993-11-10 | 1998-02-17 | Japan Tobacco Inc. | Chroman derivative and pharmaceutical use thereof |
| JPH08127594A (ja) * | 1993-11-10 | 1996-05-21 | Mochida Pharmaceut Co Ltd | Ｆａｓ抗原に結合する新規蛋白質およびそれをコードするＤＮＡ |
| US6897295B1 (en) * | 1993-11-10 | 2005-05-24 | Mochida Pharmaceutical Co., Ltd. | Antibodies and fragments thereof to Fas ligand and Fas ligand derived polypeptides |
| JP3914272B2 (ja) * | 1993-12-28 | 2007-05-16 | 中外製薬株式会社 | アドゼベリンをコードする遺伝子 |
| JP2706755B2 (ja) * | 1994-02-10 | 1998-01-28 | 日本たばこ産業株式会社 | 新規なベンジルアミノエトキシベンゼン誘導体 |
| EP1130101B1 (fr) * | 1994-06-15 | 2008-10-15 | Kirin Beer Kabushiki Kaisha | Transférase et amylase, procédé de production de ces enzymes, utilisation et gènes les codant |
| US6632976B1 (en) * | 1995-08-29 | 2003-10-14 | Kirin Beer Kabushiki Kaisha | Chimeric mice that are produced by microcell mediated chromosome transfer and that retain a human antibody gene |
| JP3193301B2 (ja) * | 1995-09-14 | 2001-07-30 | 麒麟麦酒株式会社 | 生理活性タンパク質ｐ１６０ |
| US5906819A (en) * | 1995-11-20 | 1999-05-25 | Kirin Beer Kabushiki Kaisha | Rho target protein Rho-kinase |
| US5866341A (en) * | 1996-04-03 | 1999-02-02 | Chugai Pharmaceutical Co., Ltd. | Compositions and methods for screening drug libraries |
| TW510896B (en) * | 1996-07-08 | 2002-11-21 | Kirin Brewery | Calcium receptor active compounds, the salt or hydrate thereof, and pharmaceutical composition comprising the same |
| US5785178A (en) * | 1996-11-04 | 1998-07-28 | Minnesota Mining And Manufacturing Co. | Packaged photocurable composition |
| KR100325552B1 (ko) * | 1996-12-12 | 2002-08-14 | 기린비이루가부시끼가이샤 | 신규β1→4N-아세틸글루코사미닐트랜스퍼라아제및이를코딩하는유전자 |
| TW555562B (en) * | 1996-12-27 | 2003-10-01 | Kirin Brewery | Method for activation of human antigen-presenting cells, activated human antigen-presenting cells and use thereof |
| JP2894445B2 (ja) * | 1997-02-12 | 1999-05-24 | 日本たばこ産業株式会社 | Ｃｅｔｐ活性阻害剤として有効な化合物 |
| JP3521382B2 (ja) * | 1997-02-27 | 2004-04-19 | 日本たばこ産業株式会社 | 細胞間接着及びシグナル伝達を媒介する細胞表面分子 |
| US7112655B1 (en) * | 1997-02-27 | 2006-09-26 | Japan Tobacco, Inc. | JTT-1 protein and methods of inhibiting lymphocyte activation |
| US20030064406A1 (en) * | 1997-10-08 | 2003-04-03 | Noboru Kaneko | Process for analyzing annexin-V in urine, and application thereof |
| JP2959765B2 (ja) * | 1997-12-12 | 1999-10-06 | 日本たばこ産業株式会社 | ３−ピペリジル−４−オキソキナゾリン誘導体及びそれを含有してなる医薬組成物 |
| US6562618B1 (en) * | 1997-12-25 | 2003-05-13 | Japan Tobacco, Inc. | Monoclonal antibody against connective tissue growth factor and medicinal uses thereof |
| HUP0101275A3 (en) * | 1998-03-26 | 2002-12-28 | Japan Tobacco Inc | Amide derivatives and pharmaceutical compositions containing them as nociceptin antagonists |
| TR200002904T2 (tr) * | 1998-04-10 | 2001-02-21 | Japan Tobacco Inc. | Amidin bileşikleri |
| WO1999064045A1 (fr) * | 1998-06-08 | 1999-12-16 | Advanced Medicine, Inc. | Agents therapeutiques agissant sur les transporteurs membranaires |
| AU4930299A (en) * | 1998-07-31 | 2000-02-21 | Kirin Beer Kabushiki Kaisha | Remedies for neuropathy containing as the active ingredient galectin-1 or its derivatives |
| US6506745B1 (en) * | 1998-12-28 | 2003-01-14 | Noboru Kaneko | Medicinal compositions for treatment of atrial fibrillation |
| AU754808B2 (en) * | 1999-03-30 | 2002-11-28 | Amgen Fremont Inc. | Method for preparing Monoclonal Antibody |
| WO2001016321A1 (fr) * | 1999-09-01 | 2001-03-08 | Otsuka Pharmaceutical Co., Ltd. | Adn et sequences proteiniques de glycoproteine vi (gpvi) de membranes plaquettaires et utilisations de ceux-ci |
| ATE359788T1 (de) * | 1999-09-30 | 2007-05-15 | Noboru Kaneko | Verwendung von diphenylmethylpiperazin-derivaten zur herstellung eines medikaments zur unterdrückung der proliferation von fibroblasten |
| US6568474B2 (en) * | 1999-12-20 | 2003-05-27 | Bj Services, Usa | Rigless one-trip perforation and gravel pack system and method |
| US6649366B2 (en) * | 1999-12-29 | 2003-11-18 | Smithkline Beecham Corporation | Methods and compositions related to modulators of annexin and cartilage homeostasis |
| EP1818326A1 (fr) * | 2000-01-20 | 2007-08-15 | Eisai R&D Management Co., Ltd. | Hétérocycles azotés et compositions pharmaceutiques les contenant |
| US6545170B2 (en) * | 2000-04-13 | 2003-04-08 | Pharmacia Corporation | 2-amino-5, 6 heptenoic acid derivatives useful as nitric oxide synthase inhibitors |
| AU2001249364A1 (en) * | 2000-05-03 | 2001-11-12 | Warner-Lambert Company | Treatment of congestive heart failure with a composition comprising a diuretic agent and a vasopressin antagonist |
| US20040048780A1 (en) * | 2000-05-10 | 2004-03-11 | The Trustees Of Columbia University In The City Of New York | Method for treating and preventing cardiac arrhythmia |
| US6489125B1 (en) * | 2000-05-10 | 2002-12-03 | The Trustees Of Columbia University In The City Of New York | Methods for identifying chemical compounds that inhibit dissociation of FKBP12.6 binding protein from type 2 ryanodine receptor |
| WO2002009761A2 (fr) * | 2000-07-27 | 2002-02-07 | Pharmacia Corporation | Polytherapie par antagoniste d'aldosterone epoxy-steroidien et inhibiteur calcique pour le traitement de l'insuffisance cardiaque congestive |
| TWI290130B (en) * | 2000-09-15 | 2007-11-21 | Pharmacia Corp | 2-Amino-2alkyl-5 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors |
| AR031129A1 (es) * | 2000-09-15 | 2003-09-10 | Pharmacia Corp | Derivados de los acidos 2-amino-2-alquil-4-hexenoico y -hexinoico utiles como inhibidores de oxido nitrico sintetasa |
| IL155977A0 (en) * | 2000-11-30 | 2003-12-23 | Medarex Inc | Transgenic transchromosomal rodents for making human antibodies |
| US6673904B2 (en) * | 2000-12-23 | 2004-01-06 | Kirin Beer Kabushiki Kaisha | Stem cell growth factor-like polypeptides |
| CA2437021A1 (fr) * | 2001-02-01 | 2002-08-08 | Mochida Pharmaceutical Co., Ltd. | Proteine associee a l'adiponectine |
| JP4817514B2 (ja) * | 2001-03-09 | 2011-11-16 | 協和発酵キリン株式会社 | 新規動物細胞用ベクターおよびその使用 |
| CA2440374A1 (fr) * | 2001-03-14 | 2002-09-19 | Takayuki Maruyama | Composition pharmaceutique pour le traitement de la depression comprenant un antagoniste ep1 en tant que principe actif |
| US20030054531A1 (en) * | 2001-03-19 | 2003-03-20 | Decode Genetics Ehf, | Human stroke gene |
| DE60208364T2 (de) * | 2001-04-27 | 2006-09-28 | Kirin Beer K.K. | Chinolinderivate mit einer azolylgruppe und chinazolinderivate |
| US6869975B2 (en) * | 2001-09-14 | 2005-03-22 | Tularik Inc. | Linked biaryl compounds |
| JP2003145746A (ja) * | 2001-11-16 | 2003-05-21 | Seiko Epson Corp | インクジェット記録方法及びインクジェット記録装置 |
| WO2003043655A1 (fr) * | 2001-11-19 | 2003-05-30 | Ono Pharmaceutical Co., Ltd. | Remedes pour la frequence urinaire |
| US7163952B2 (en) * | 2001-12-03 | 2007-01-16 | Japan Tobacco Inc. | Azole compound and medicinal use thereof |
| AU2003207431A1 (en) * | 2002-01-17 | 2003-09-02 | Pharmacia Corporation | Novel alkyl/aryl hydroxy or keto thiepines. |
| JPWO2003090570A1 (ja) * | 2002-04-26 | 2005-08-25 | 日本たばこ産業株式会社 | 棒状物品の成形装置 |
| JP4113042B2 (ja) * | 2002-05-24 | 2008-07-02 | シチズンホールディングス株式会社 | 表示装置およびカラー表示方法 |
| ES2277142T3 (es) * | 2002-08-30 | 2007-07-01 | Japan Tobacco Inc. | Compuesto de dibencilamina y su uso medicinal. |
| US20050032210A1 (en) * | 2003-03-18 | 2005-02-10 | Kirin Beer Kabushiki Kaisha | Method of preparing immuno-regulatory dendritic cells and the use thereof |
| US20050009733A1 (en) * | 2003-04-22 | 2005-01-13 | Pharmacia Corporation | Compositions of a cyclooxygenase-2 selective inhibitor and a potassium ion channel modulator for the treatment of central nervous system damage |
| TWI494102B (zh) * | 2003-05-02 | 2015-08-01 | Japan Tobacco Inc | 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合 |
| WO2005016249A2 (fr) * | 2003-07-11 | 2005-02-24 | Pharmacia Corporation | Compositions constituees d'un inhibiteur chromene ou acide phenylacetique selectif de la cyclooxygenase-2 et d'un inhibiteur de ace pour traiter les lesions du systeme nerveux central |
| JP2007501801A (ja) * | 2003-08-07 | 2007-02-01 | 日本たばこ産業株式会社 | ピロロ［１，２−ｂ］ピリダジン誘導体 |
| EP1670459A4 (fr) * | 2003-08-20 | 2009-03-25 | Nitromed Inc | Composes cardiovasculaires nitroses et nitrosyles, compositions et procedes d'utilisation |
| JP2007504136A (ja) * | 2003-08-28 | 2007-03-01 | ニトロメッド インコーポレーティッド | ニトロソ化およびニトロシル化利尿化合物、組成物、ならびに使用方法 |
| CA2563064A1 (fr) * | 2004-04-22 | 2005-11-10 | Kirin Beer Kabushiki Kaisha | Animaux transgeniques et leurs utilisations |
| US7378423B2 (en) * | 2004-06-11 | 2008-05-27 | Japan Tobacco Inc. | Pyrimidine compound and medical use thereof |
| JP3968358B2 (ja) * | 2004-06-30 | 2007-08-29 | 日本電信電話株式会社 | 薄型フラットツイストぺアすきまケーブル及びすきまナビゲータユニット |
| WO2006006741A1 (fr) * | 2004-07-15 | 2006-01-19 | Japan Tobacco Inc. | Composé benzamide fusionné et inhibiteur d'activité récepteur vanilloïde 1 (vr1) |
| AR051780A1 (es) * | 2004-11-29 | 2007-02-07 | Japan Tobacco Inc | Compuestos en anillo fusionados que contienen nitrogeno y utilizacion de los mismos |
| US7704990B2 (en) * | 2005-08-25 | 2010-04-27 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
-
2003
- 2003-10-07 US US10/680,988 patent/US20040229781A1/en not_active Abandoned
-
2004
- 2004-10-04 JP JP2006534204A patent/JP2007507536A/ja not_active Abandoned
- 2004-10-04 CN CNB2004800346080A patent/CN100502845C/zh not_active Expired - Fee Related
- 2004-10-04 KR KR1020067008775A patent/KR20060110290A/ko not_active Ceased
- 2004-10-04 AU AU2004281672A patent/AU2004281672A1/en not_active Abandoned
- 2004-10-04 BR BRPI0415434-7A patent/BRPI0415434A/pt not_active IP Right Cessation
- 2004-10-04 EP EP04794052A patent/EP1684735A4/fr not_active Withdrawn
- 2004-10-04 WO PCT/US2004/032550 patent/WO2005037195A2/fr not_active Ceased
- 2004-10-04 SG SG200807427-0A patent/SG147414A1/en unknown
- 2004-10-04 EA EA200600740A patent/EA011357B1/ru not_active IP Right Cessation
- 2004-10-04 CA CA002541847A patent/CA2541847A1/fr not_active Abandoned
-
2006
- 2006-05-02 MA MA28995A patent/MA28146A1/fr unknown
- 2006-05-05 ZA ZA200603593A patent/ZA200603593B/xx unknown
- 2006-05-08 NO NO20062063A patent/NO20062063L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005037195A2 (fr) | 2005-04-28 |
| AU2004281672A1 (en) | 2005-04-28 |
| BRPI0415434A (pt) | 2006-12-05 |
| CN100502845C (zh) | 2009-06-24 |
| JP2007507536A (ja) | 2007-03-29 |
| US20040229781A1 (en) | 2004-11-18 |
| SG147414A1 (en) | 2008-11-28 |
| WO2005037195A3 (fr) | 2005-12-01 |
| EP1684735A2 (fr) | 2006-08-02 |
| CN1886122A (zh) | 2006-12-27 |
| KR20060110290A (ko) | 2006-10-24 |
| EA200600740A1 (ru) | 2006-10-27 |
| MA28146A1 (fr) | 2006-09-01 |
| ZA200603593B (en) | 2010-10-27 |
| EA011357B1 (ru) | 2009-02-27 |
| CA2541847A1 (fr) | 2005-04-28 |
| EP1684735A4 (fr) | 2009-01-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA96914C2 (ru) | Производные 1,4-бензотиазепина, их применение при сердечной недостаточности, фармацевтическая композиция, которая их содержит, и способ лечения | |
| SI3072978T1 (sl) | 1L1RL-1 kot marker za kardiovaskularne bolezni | |
| DE60312017D1 (de) | Sulfonderivate zur hemmung von gamma-secretase | |
| ATE368031T1 (de) | Neue gamma secretase inhibitoren | |
| EA200702057A1 (ru) | Новые антиаритмические и применяемые при сердечной недостаточности лекарственные средства, которые направлены против "просачивания" рецептора рианодина (ryr2) | |
| NO20072286L (no) | Hemming av HCV NS3-NS4A-protease | |
| SG147414A1 (en) | Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias | |
| ATE443043T1 (de) | Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer | |
| TNSN02008A1 (fr) | Derives d'acides isophtalique nouveaux inhibiteurs de mmp, et compositions les contenant | |
| ATE464287T1 (de) | Cyclohexyl-sulphone als gamma-sekretase- inhibitoren | |
| ATE470445T1 (de) | Verwendung von ranolazin zur herstellung eines medikaments zur behandlung von frühen nachdepolarisationen (eads) | |
| TNSN02021A1 (fr) | Derives de benzimidazole nouveaux, et compositions les contenant | |
| NO913923D0 (no) | 17beta-substituerte-4-aza-5alfa-androstan-3-on-derivater ogfremgangsmaate ved fremstilling av disse | |
| ATE401314T1 (de) | Benzodiazepin-derivate als gamma-secretase inhibitoren | |
| DE60140695D1 (de) | Anilinopyrimidinderivate als ikk?inhibitoren, und hiermit in zusammenhang stehende zusammensetzungen und verfahren | |
| NO962568L (no) | Anvendelse av PLA2 inhibitorer som behandling for Alzheimers sykdom | |
| NO952129L (no) | Oksalylamino-benzofuran- og benzotienyl-derivater | |
| PL1685142T3 (pl) | Pochodne kwasu fosfinowego, inhibitory beta-sekterazy do leczenia choroby Alzheimera | |
| LT2002099A (en) | Sustained release beadlets containing stavudine | |
| CHOPRA et al. | Free radical scavenging: a potentially beneficial action of thiol-containing angiotensin converting enzyme inhibitors | |
| ATE423102T1 (de) | 4-substituirte-5-cyano-1h-pyrimidin-6-(th)iones als als gsk-3-hemmer | |
| TR200103561T2 (tr) | Rodanin türevleri ve amiloidlerin önlenmesi ve görüntülenmesinde kullanımları | |
| ATE419037T1 (de) | Verwendung eines mittel zur therapie der herzhypertrophie | |
| MXPA05011428A (es) | Metodo de tratamiento de fibrilacion atrial o trepidacion auricular. | |
| NO20033541L (no) | Anvendelse av fosfodiesteraseinhibitorer av type 4 ved hjertemuskelsykdommer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |